share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K:外国发行人报告
SEC announcement ·  04/09 16:05
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale...Show More
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale School of Medicine. Clearmind also reported progress in obesity and metabolic disorders research, a collaboration with CTS Ltd., and the expansion of its patent portfolio. Looking forward, Clearmind anticipates initiating the Phase I/IIa trial for AUD, expanding strategic alliances, advancing obesity research, and progressing its MEAI-based alcohol substitute for the consumer market. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
处于临床阶段的生物技术公司Clearmind Medicine Inc. 已于2024年4月9日致股东的一封信,概述了其研发工作的重大进展,特别是其旗舰化合物 CMND-100 的研发进展。首席执行官阿迪·祖洛夫-沙尼博士重点介绍了该公司在治疗酒精使用障碍(AUD)和其他心理健康状况方面取得的进展。Clearmind 已获得以色列卫生部的批准,可进行 CMND-100 的 I/IIa 期临床试验,该试验在临床前研究中显示出令人鼓舞的结果,不会诱发幻觉。该公司已经完成了与美国食品药品管理局的A型会议,成立了数据和安全监测委员会,获得了以色列IRB的批准,并宣布在约翰·霍普金斯大学和耶鲁医学院设立...展开全部
处于临床阶段的生物技术公司Clearmind Medicine Inc. 已于2024年4月9日致股东的一封信,概述了其研发工作的重大进展,特别是其旗舰化合物 CMND-100 的研发进展。首席执行官阿迪·祖洛夫-沙尼博士重点介绍了该公司在治疗酒精使用障碍(AUD)和其他心理健康状况方面取得的进展。Clearmind 已获得以色列卫生部的批准,可进行 CMND-100 的 I/IIa 期临床试验,该试验在临床前研究中显示出令人鼓舞的结果,不会诱发幻觉。该公司已经完成了与美国食品药品管理局的A型会议,成立了数据和安全监测委员会,获得了以色列IRB的批准,并宣布在约翰·霍普金斯大学和耶鲁医学院设立美国临床试验基地。Clearmind还报告了肥胖和代谢障碍研究的进展、与CTS有限公司的合作以及其专利组合的扩大。展望未来,Clearmind预计将启动澳元的I/IIa期试验,扩大战略联盟,推进肥胖研究,并推进其基于MEAI的酒精替代品在消费市场上取得进展。该公司的股票在纳斯达克和法兰克福证券交易所上市,股票代码分别为 “CMND” 和 “CWY0”。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息